Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review

Overview

Journal Crit Care Med

Specialties Critical Care
Emergency Medicine

Date 2020 Jul 25

PMID 32706554

Citations 6

Authors

Lindsay M Busch

Junfeng Sun

Peter Q Eichacker

Parizad Torabi-Parizi

Affiliations

Soon will be listed here.

Abstract

Objectives: Checkpoint inhibitors have been proposed for sepsis following reports of increased checkpoint molecule expression in septic patients. To determine whether clinical studies investigating checkpoint molecule expression provide strong evidence supporting trials of checkpoint inhibitors for sepsis.

Data Sources: PubMed, EMBASE, Scopus, Web of Science, inception through October 2019.

Study Selection: Studies comparing checkpoint molecule expression in septic patients versus healthy controls or critically ill nonseptic patients or in sepsis nonsurvivors versus survivors.

Data Extraction: Two investigators extracted data and evaluated study quality.

Data Synthesis: Thirty-six studies were retrieved. Across 26 studies, compared with healthy controls, septic patients had significantly (p ≤ 0.05) increased CD4+ lymphocyte programmed death-1 and monocyte programmed death-ligand-1 expression in most studies. Other checkpoint molecule expressions were variable and studied less frequently. Across 11 studies, compared with critically ill nonseptic, septic patients had significantly increased checkpoint molecule expression in three or fewer studies. Septic patients had higher severity of illness scores, comorbidities, and mortality in three studies providing analysis. Across 12 studies, compared with septic survivors, nonsurvivors had significantly increased expression of any checkpoint molecule on any cell type in five or fewer studies. Of all 36 studies, none adjusted for nonseptic covariates reported to increase checkpoint molecule expression.

Conclusions: Although sepsis may increase some checkpoint molecule expression compared with healthy controls, the data are limited and inconsistent. Further, data from the more informative patient comparisons are potentially confounded by severity of illness. These clinical checkpoint molecule expression studies do not yet provide a strong rationale for trials of checkpoint inhibitor therapy for sepsis.

Citing Articles

Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression.

Luo J, Zhang C, Chen D, Chang T, Chen S, Lin Z Eur J Med Res. 2024; 29(1):583.

PMID: 39696711 PMC: 11656820. DOI: 10.1186/s40001-024-02203-w.

Pneumonia in the first week after polytrauma is associated with reduced blood levels of soluble herpes virus entry mediator.

Schaefer N, Lindner H, Hahn B, Schefzik R, Velasquez S, Schulte J Front Immunol. 2024; 14:1259423.

PMID: 38187375 PMC: 10770833. DOI: 10.3389/fimmu.2023.1259423.

Role of regulation of PD-1 and PD-L1 expression in sepsis.

Zhang T, Yu-Jing L, Ma T Front Immunol. 2023; 14:1029438.

PMID: 36969168 PMC: 10035551. DOI: 10.3389/fimmu.2023.1029438.

Immune hyporeactivity to bacteria and multiple TLR-ligands, yet no response to checkpoint inhibition in patients just after meeting Sepsis-3 criteria.

Bick A, Buys W, Engler A, Madel R, Atia M, Faro F PLoS One. 2022; 17(8):e0273247.

PMID: 35981050 PMC: 9387870. DOI: 10.1371/journal.pone.0273247.

Resolving sticky relationships between platelets and lymphocytes in COVID-19: A role for checkpoint inhibitors?.

Torabi-Parizi P, Suffredini A Br J Haematol. 2022; 197(3):247-249.

PMID: 35132612 PMC: 9111338. DOI: 10.1111/bjh.18095.

References

Monaghan S, Banerjee D, Chung C, Lomas-Neira J, Cygan K, Rhine C . Changes in the process of alternative RNA splicing results in soluble B and T lymphocyte attenuator with biological and clinical implications in critical illness. Mol Med. 2018; 24(1):32. PMC: 6016894. DOI: 10.1186/s10020-018-0036-3. View

Liu M, Zhang X, Chen H, Wang G, Zhang J, Dong P . Serum sPD-L1, Upregulated in Sepsis, May Reflect Disease Severity and Clinical Outcomes in Septic Patients. Scand J Immunol. 2016; 85(1):66-72. DOI: 10.1111/sji.12509. View

Monneret G, Debard A, Venet F, Bohe J, Hequet O, Bienvenu J . Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med. 2003; 31(7):2068-71. DOI: 10.1097/01.CCM.0000069345.78884.0F. View

Tomino A, Tsuda M, Aoki R, Kajita Y, Hashiba M, Terajima T . Increased PD-1 Expression and Altered T Cell Repertoire Diversity Predict Mortality in Patients with Septic Shock: A Preliminary Study. PLoS One. 2017; 12(1):e0169653. PMC: 5225000. DOI: 10.1371/journal.pone.0169653. View

Thompson K, Taylor C, Jan S, Li Q, Hammond N, Myburgh J . Health-related outcomes of critically ill patients with and without sepsis. Intensive Care Med. 2018; 44(8):1249-1257. DOI: 10.1007/s00134-018-5274-x. View

Osuchowski M, Ayala A, Bahrami S, Bauer M, Boros M, Cavaillon J . Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis. Infection. 2018; 46(5):687-691. PMC: 6182493. DOI: 10.1007/s15010-018-1183-8. View

Daud A, Wolchok J, Robert C, Hwu W, Weber J, Ribas A . Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016; 34(34):4102-4109. PMC: 5562434. DOI: 10.1200/JCO.2016.67.2477. View

Shao R, Li C, Fang Y, Zhao L, Hang C . Low B and T lymphocyte attenuator expression on CD4+ T cells in the early stage of sepsis is associated with the severity and mortality of septic patients: a prospective cohort study. Crit Care. 2015; 19:308. PMC: 4556404. DOI: 10.1186/s13054-015-1024-4. View

Weyand C, Berry G, Goronzy J . The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease. J Leukoc Biol. 2017; 103(3):565-575. PMC: 6457250. DOI: 10.1189/jlb.3MA0717-283. View

10.

Huang X, Venet F, Wang Y, Lepape A, Yuan Z, Chen Y . PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A. 2009; 106(15):6303-8. PMC: 2669369. DOI: 10.1073/pnas.0809422106. View

11.

Callahan M, Postow M, Wolchok J . Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016; 44(5):1069-78. DOI: 10.1016/j.immuni.2016.04.023. View

12.

Busch L, Sun J, Cui X, Eichacker P, Torabi-Parizi P . Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. Intensive Care Med Exp. 2020; 8(1):7. PMC: 7000606. DOI: 10.1186/s40635-019-0290-x. View

13.

Niu B, Zhou F, Su Y, Wang L, Xu Y, Yi Z . Different Expression Characteristics of LAG3 and PD-1 in Sepsis and Their Synergistic Effect on T Cell Exhaustion: A New Strategy for Immune Checkpoint Blockade. Front Immunol. 2019; 10:1888. PMC: 6693426. DOI: 10.3389/fimmu.2019.01888. View

14.

Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F . Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care. 2011; 15(2):R99. PMC: 3219369. DOI: 10.1186/cc10112. View

15.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

16.

Hotchkiss R, Monneret G, Payen D . Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013; 13(12):862-74. PMC: 4077177. DOI: 10.1038/nri3552. View

17.

Xia Q, Wei L, Zhang Y, Sheng J, Wu W, Zhang Y . Immune Checkpoint Receptors Tim-3 and PD-1 Regulate Monocyte and T Lymphocyte Function in Septic Patients. Mediators Inflamm. 2019; 2018:1632902. PMC: 6282152. DOI: 10.1155/2018/1632902. View

18.

Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M . Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis. 2017; 56:221-228. DOI: 10.1016/j.ijid.2017.01.028. View

19.

Elias R, Hartshorn K, Rahma O, Lin N, Snyder-Cappione J . Aging, immune senescence, and immunotherapy: A comprehensive review. Semin Oncol. 2018; 45(4):187-200. DOI: 10.1053/j.seminoncol.2018.08.006. View

20.

Lee J, Spidlen J, Boyce K, Cai J, Crosbie N, Dalphin M . MIFlowCyt: the minimum information about a Flow Cytometry Experiment. Cytometry A. 2008; 73(10):926-30. PMC: 2773297. DOI: 10.1002/cyto.a.20623. View